HepaLife Technologies
 
Home Corporate Bioartificial Liver Clinical Trials Investors Contact

SEC Filings

Disclaimer

HepaLife's Securities and Exchange Commission (SEC) filings can be accessed by clicking the link below. This link will take you directly to the U.S. Securities and Exchange Commission website which is is located on another server.

bullet Click here to view HepaLife's SEC Filings

News

Bullet 06/22/2009
Independent report projects HepaLife™ as a leader in $1.5 billion liver assist market

>>More Info

 

Animations

Click here to view animation

Click here to see
how HepaMate™ works



Home   |   Corporate   |   Bioartificial Liver   |   Clinical Trials   |   Investors   |   Contact   |   Disclaimer
© Copyright 2009 HepaLife Technologies, Inc.    All Rights Reserved.